(Q39575152)

13 September 2017

Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts (English)

1 reference

13 September 2017

1 reference

myelodysplastic syndrome

1 reference

inferred from title

acute erythroid leukemia

1 reference

Sa A Wang

1

1 reference

13 September 2017

Keyur P Patel

2

1 reference

13 September 2017

Olga Pozdnyakova

3

1 reference

13 September 2017

Jie Peng

4

1 reference

13 September 2017

Zhuang Zuo

5

1 reference

13 September 2017

Paola Dal Cin

6

1 reference

13 September 2017

David P Steensma

7

1 reference

13 September 2017

Robert P Hasserjian

8

1 reference

13 September 2017

22 July 2016

1 reference

13 September 2017

1 reference

13 September 2017

29

1 reference

13 September 2017

1221-1231

1 reference

13 September 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2016.118

13 September 2017

0 references

cites work

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

How unique is pure erythroid leukaemia? A retrospective analysis of seven cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Therapy-related myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Erythroleukaemia in the north of England: a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2016.118

Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation

21 January 2018

1 reference

12 December 2020

High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome

1 reference

12 December 2020

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

12 December 2020

Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia

1 reference

12 December 2020

Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin

1 reference

12 December 2020

10.1038/MODPATHOL.2016.118

Identifiers

DOI

1 reference

13 September 2017

1 reference